Hepatoren ®$_{ }$ Vaprisol ®$_{ }$ Cumberland’s newest drug, Vaprisol ® , is a  prescription product indicated for the treatment  of hospitalized patients with hyponatremia, a  common electrolyte disturbance in which the  sodium ion concentration in blood plasma is lower  than normal. Hyponatremia can be associated  with a variety of critical care conditions including  congestive heart failure, liver failure, kidney failure,  cancer and pneumonia. Because the symptoms of  hyponatremia can be subtle, it can go unrecognized  and untreated – often resulting in longer hospital  stays or poor outcomes.  As one of only two branded products indicated for  the treatment of hyponatremia, Vaprisol is the first  and only intravenously administered vasopressin  receptor antagonist. It works by reducing excess  water to increase serum sodium concentration and  regulate the water/sodium balance in hospitalized  patients. Because it is used exclusively in hospitals,  the product complements the activities of the  Company’s hospital sales force, which promotes  Acetadote and Caldolor.  Developed and launched commercially by Astellas  Pharma US in 2006, Cumberland announced the  acquisition of Vaprsiol in March 2014. Following the  launch of a promotional campaign to support the  product, our sales force began actively marketing  it in May with many physicians expressing their  interest in seeing support for this product return. Hepatoren is progressing through clinical  development in patients suffering from life- threatening liver and kidney failure. We continue to  evaluate the product in a group of leading medical  research centers across the U.S.  Cumberland acquired the rights to ifetroban from  Cumberland Emerging Technologies (CET) in early  2011 and began developing it under the brand  name Hepatoren. Ifetroban had previously been  developed by a large pharmaceutical company  through seven Phase II studies targeting significant  cardiovascular indications. That development  program did not meet all of its goals for these  indications, and the product was subsequently  donated to Vanderbilt University. Researchers at  Vanderbilt identified ifetroban as a safe, active, and  potentially valuable compound in treating patients  for several new indications. Vanderbilt partnered  with CET, Cumberland’s majority-owned subsidiary,  to transfer all of the data and manufacturing  associated with this product. Hepatoren ®  is being developed as an injectable  formulation to treat patients suffering from  hepatorenal syndrome, a life-threatening condition  involving progressive kidney failure for which there  is no FDA approved pharmaceutical treatment.  Approximately 450,000 patients in the United States  suffer from medical conditions that make them  susceptible to cirrhosis and a subset of these  patients develop hepatorenal syndrome every year.  Amy Dix Rock, Ph.D. | Senior Director,  Regulatory & Scientific Affairs Cumberland Pharmaceuticals “Whether reintroducing a brand to the market or developing a new product candidate, our goal is the  same: to provide innovative solutions that address poorly met medical needs. Both of these products  not only represent significant opportunity for our Company, but also offer promising treatment for  critically ill patients.” 9